What is the current price and volume for GV.PA stock?

GV.PA stock is trading pre-market at **€0.0018** with volume **38,489,238** shares, about 2.71x the 50-day average. Day range is **€0.0015–€0.0020** and previous close was **€0.0017**.

What grade does Meyka AI give GV.PA stock and why?

Meyka AI rates GV.PA **62.66/100 (Grade B: HOLD)**. The grade uses S&P 500 and sector comparisons, financial growth, key metrics, forecasts and analyst data. These grades are informational and not financial advice.

What are the main risks for investors in GV.PA stock?

Main risks include very low liquidity, negative earnings (EPS **-0.11**), a weak current ratio **0.91**, reliance on a few commercial partners and long inventory cycles. Small-cap moves can be sudden and high-loss if not sized correctly.

What price target does Meyka AI forecast for GV.PA stock?

Meyka AI's forecast model projects a 12-month target of **€0.0050**, compared with the current **€0.0018**, implying **+177.78%** upside. Forecasts are model-based projections and not guarantees.

EU Stocks

GV.PA Genomic Vision SA EURONEXT pre-market 26 Feb 2026: High volume, key impact

ByHuzaifa Zahoor February 26, 2026February 26, 2026

GV.PA stock is trading at €0.0018 pre-market on EURONEXT after a +5.88% intraday move and unusually high volume of 38,489,238 shares. The spike puts Genomic Vision SA (GV.PA) at the top of most-active lists for Europe healthcare micro-caps. Volume is 2.71x the average, suggesting short-term liquidity and heightened trader interest. We summarise what the numbers mean for valuation, catalysts and risk ahead of next news and the company’s positioning in diagnostics.